Summary
Summary

1.
Aquaporins are targets for drug discovery for basic research and medicine. Human diseases involving fluid imbalances and oedema are of major concern, and involvet issues in which aquaporins are expressed. The range of functional properties of aquaporins is continuing to expand steadily with ongoing research in the field.
2. Gating domains in aquaporins (AQPs) are molecular sites for drug actions. Discovery of the arylsulfonamide AqB013 as an antagonist for AQP1 and AQP4 provided the first pharmacological agent with translational promise for the treatment of diseases in which AQPs have been implicated. The putative binding site for AqB013 in the internal vestibule of the AQP water pore involves amino acid residues that are located in the AQP loop D gating domain.
3. Aquaporins have been proposed as noveltargets in cancer and oedema, and are associated with a surprising array of important processes in the brain and body such as angiogenesis, cell migration, development, and neuropathological diseases. Functions beyond their simple role as water channels are suggested by the subtype-specific regulation of AQP expression. In both cancer and brain oedema, current therapies are limited, and new pharmacological approaches focused on AQPs offer exciting potential for clinical advances.
Aquaporins aretargets for drug discovery for basic research and medicine
Aquaporins are integral membrane proteins that enable the movement of water and other small solutes across biological membranes. 1 With continuing research on aquaporins, the repertoire nowi ncludes permeabilities in some subtypes of aquaporins to a variety of substrates including gasses 2 and ions. 3 As members of the Major Intrinsic Protein (MIP) family,a quaporins have been identified in almost every living organism, including vertebrates, invertebrates, plants, and bacteria. The 13 mammalian classes of aquaporins (AQP0-12) generally are divided into twoc ategories: the aquaporins, which primarily transport water,and the aquaglyceroporins, which also allowpermeation of small solutes such as glycerol and urea.
Aquaporin-1
AQP1 was the first water channel to be characterized 4, 5 from studies of erythrocyte membrane proteins. Previously known as CHIP28 (channel-like integral protein, 28 kDa), Aquaporin-1 mediates osmotic and hydrostatic water fluxes across cell membranes. AQP1 is found in a variety of tissues including kidneyp roximal tubule, eye, heart, lung, the vascular system, and in the choroid plexus in brain ventricles. [6] [7] [8] [9] [10] Exemplifying a general pattern of AQP structural organisation, each subunit in the AQP1 tetrameric channel comprises six full transmembrane domains, connected by intracellular and extracellular loops with cytoplasmic N-and C-termini ( Figure 1 ).
Domains within loop B (between transmembrane domains 2 and 3) and loop E (between transmembrane domains 5 and 6) fold into the lipid bilayer from opposite sides of the membrane to form the subunit aqueous pore, first conceptualized as an "hourglass" model 11 as an insight that was generally validated by later crystal structural analyses. 12 to dissect the roles of aquaporins in physiological and pathological processes is clear,progress in the development of selective non-toxic pharmacological agents for AQP channels has been slow. The classic blocker of AQP1 is the mercuric ion Hg 2+ 16 buti ts high toxicity precludes any therapeutic consideration. Site-directed mutagenesis of human AQP1 identified the binding site for Hg 2+ as a cysteine residue (Cys189) located extracellularly in loop E, 16 at which covalent modification is thought to block water permeability by occluding the pore. Other heavy metals such as silver and gold 17 also inhibit AQP1 water channel function. The carbonic anhydrase inhibitor acetazolamide (10 µM) was found to reduce water permeability by >80% in AQP1-expressing Xenopus oocytes 18 and in AQP1-transfected HEK cells. 19 Prior work from our laboratory identified the quaternary ammonium, tetraethylammonium ion (TEA + ), as the first non-mercurial compound to inhibit AQP1 function. 20 With human AQP1 channels expressed in Xenopus oocytes, the application of extracellular TEA resulted in a modest dose-dependent reduction in osmotically-drivens welling rate, blocking water channel function by approximately 30% at 10 mM. TEA-Cl reduced water permeability in AQP1-expressing MDCK cells and in rat kidneydescending thin limb 21 indicating the block also was effective onn atively expressed channels. The sensitivity of human AQP1 to TEA was removedb y site-directed mutagenesis of Tyr186 to Phe (Y186F) in the outer vestibule of the AQP1 water pore, confirming that the inhibitory effect of TEA was mediated directly at the AQP1 channel. 20 The block of AQP1 by TEA was confirmed independently,a nd extended to include other classes of AQPs which have tyrosine at the position homologous to Y186 in AQP1. 22 Although a separate study failed to confirm TEA blocking activity, 23 TEA has successfully been used as an aquaporin inhibitor in other preparations. 24, 25 The agents summarized above (metal ions, tetraethylammonium, acetazolamide) are valuable in that theyindicate pharmacological modification of AQP activity is possible, but theyl ack the specificity or efficacyn eeded for a clear translational value. Our discovery of a novel blocker (AqB013) for AQP1 ( Figure 2 ) and AQP4 channels, and the identification of the putative binding site on the intracellular vestibule of the water channel pore, 26 suggest opportunities for translational applications. Targets of treatment include oedema in brain, lung and heart, glaucoma, cancer,r enal dysfunction and other conditions involving alterations in fluid transport and homeostasis in AQP-expressing tissues. 14 
Aquaporin-4
In the mammalian brain, the predominant class of water channel is AQP4, which is localized in astroglial cells throughout the brain and spinal cord near the bloodbrain-barrier interface, 27 and thought to play a major role in brain fluid homeostasis. It is also expressed in other tissues including lung, skeletal muscle and collecting ducts of the kidney. 28, 29 In contrast to AQP1, AQP4 is insensitive to mercurial inhibition. 28, 30 Atypically,r at AQP4 channels reconstituted in proteoliposomes showam ercury-sensitive water permeability that involves Cys178 in the loop D region, 31 as ite that normally is inaccessible on the intracellular side. The residue in the equivalent position in AQP1 is threonine (T157 in human AQP1).
Arylsulfonamides are a class of compounds characterized by an aromatic benzene ring attached to a sulfonamide group, SO 2 NH 2 ( Figure 3 ). This class of compounds shows promise for development of pharmacological agents for aquaporins. Sulfonamides such as the carbonic anhydrase inhibitor acetazolamide can reduce AQP4 activity. 32 Anti-epileptic drugs such as topiramate and zonisamide recently have been found to have inhibitory effects on AQP4 function. 33 Discovery of the arylsulfonamide AqB013 as an antagonist for AQP1 and AQP4 was based on a combination of synthetic chemistry,b iological assays, and in silico modeling. Bumetanide wass elected as the structural scaffold for design of a chemical library of derivativesb ased on a small but significant block of AQP4 water channel function. 26 Bumetanide is known as a loop diuretic drug which inhibits the Na-K-2Cl cotransporter in the kidneya scending limb of Henle. 34 Inhibiting the Na-K-2Cl cotransporter in the kidneyd ecreases Na + reabsorption and increases water excretion, resulting in diuresis. At doses higher than those needed for loop diuretic activity,b umetanide has a protective effect on rat brain oedema. 35, 36 Brain oedema and infarct volumes were reduced by application of approximately 100 µM bumetanide in cerebrospinal fluid saline, 37, 38 whereas the concentration required to block the cotransporter is more than 50-fold lower. The AqB series of bumetanide derivativesw as tested on AQP1 and -4 channels expressed in Xenopus oocytes, assayed by videomicroscopic analysis of swelling rates. AqB013 produced half maximal block (IC 50 )at ∼20 µMfor both AQP1 and -4, and had comparatively little effect on Na-K-2Cl transport. Collaborative studies on the effects of AqB013 in vivo and in vitro are in progress to assess effects of this compound in cell and systems models of pathophysiology.T his novelc lass of pharmacological agents for aquaporins could be valuable as adjuncts in treating oedema and other conditions involving fluid imbalance in aquaporin-expressing tissues.
Gating domains in aquaporins (AQPs) aremolecular sites for drug actions
Crystal-structure data for AQPs allowed structural modelling and the prediction of putative binding sites on AQP4. 26 In silico analyses were used to resolvet hree putative binding site cavities: twoo nt he intracellular side of the AQP4 subunit, labelled as Sites 1 and 2, and one extracellular,l abelled as Site 3 ( Figure 4 ). Site-directed mutations of AQP4 were used to test for amino acid residues that contributed to the candidate binding sites. Changes at Site 1 altered efficacyofblock by AqB013, thus showing that the aquaporin channel is the direct molecular target of action. Site 1 is located at the intracellular vestibule of the water pore, and involves the loop D region. The mutations of Ser180 to Arg(S180R), and Val189 to Ala (V189A) both significantly enhanced the blocking effect of 50 µM AqB013 as compared with wild type AQP4. 26 The residues Ser180 and Val189 in rat AQP4 which interact with AqB013 are equivalent to Ser180 and Ile189 in human AQP4 ( Figure 5 ), and are located in the intracellular loop D. AqB013 block at the equivalent position in human AQP1 would involvet he loop D residues Arg159 and Ala168, which were recapitulated in the selection of substitute residues for the AQP4 modifications. The wild type AQP1 channel with the Argand Ala residues naturally in place does not showh igher sensitivity to block by AqB013 as compared with AQP4, suggesting that additional residues contribute to the putative docking site.
The loop D domain has been proposed to servei n gating AQP channel functions in mammalian AQP1, 39 and AQP4, 40, 41 and in plant AQP. 42 In AQP1, the loop D domain is involved in regulation of a non-selective monovalent cation channel activity,a ctivated by cGMP signalling. Although AQP1 is a robust water channel, under permissive conditions, it also functions as an ion channel. 9, [43] [44] [45] The subunits of the aquaporin channel are organized as tetramers spanning the cell membrane, and the passage of water and ions appears to be through pharmacologically distinct pathways, with conduction of ions occurring through the putative central pore sensitive to Cd 2+ butn ot TEA +3 9,46 and water transport occurring through the individual pores located in each subunit sensitive toT EA + butn ot Cd 2+ . 11 Development of The candidate residues of Sites 1 and 2 are located mainly in intracellular loops B and D, but Site 2 also includes the C-terminal region of AQP4, based on structural modelling. The C-terminal region has been proposed to be involved in AQP1 regulation because it carries a consensus sequence for Ca 2+ binding. 41 As illustrated by the effects of site-directed mutations, the C-terminal domain modulates the ionic conductance of the AQP1 channel. 39, 45, 47, 48 Activation of protein kinase C by phorbol esters increases the AQP1 cationic current by a mechanism that is dependent on phosphorylation of Thr157 and Thr239 residues 45 located in loop D and in the C-terminus, respectively.I nS ite 2, an Argr esidue in the carboxyl terminus is conserved (243 in bAQP1; 261 in rAQP4). In continuing work, it will be of interest to determine whether anyofthe arylsulfonamide-related derivativescan be found to act at Site 2, at which possible modulatory effects on the water or ion fluxes might be identified. Such tools will be valuable for addressing the physiological purpose of dual channel function in the aquaporins that are both ion and water channels, such as AQP0, 49 ,50 AQP1 43,44 and AQP6, 51 and potentially other AQP ion channels yet to be identified.
AQPpharmacological drug agents hold translational promise for fluid imbalance disorders such as brain oedema and diseases such as cancer
Calls for the development of aquaporin blockers have been drivenb yr ecognition of the protective effects of genetic aquaporin deficiencya gainst pathological fluid accumulation and disease processes in mouse models. AQPs have ano bvious role in mediating fluid homeostasis, buta lso have been associated with diverse other processes including angiogenesis, cell migration, development, neuropathological disease, and cancer,through mechanisms that are not yet understood. Examples of twoa reas of particular interest for investigating translational value of the AqB compounds include treating brain oedema, and as a possible adjunct for novelstrategies of cancer treatment.
Brain oedema
Brain oedema is a potentially fatal consequence of head injury,b rain tumour,s troke, and infections such as meningitis, all of which cause brain swelling due to excess fluid accumulation. 29, [52] [53] [54] Cerebral oedema is the leading cause of mortality and morbidity associated with head trauma and stroke. 55 Current treatments include neurosurgical decompression and administration of hyperosmolar agents to extract brain water osmotically. 56, 57 AQP4 is postulated to play a critical role in the formation of brain oedema after stroke, injury or water intoxication. Decreased AQP4 expression in mammals can reduce the rate of pathological fluid accumulation in the brain, and AQP4 deficient mice showimprovedoutcomes in models of brain oedema. AQP4-null mice demonstrated reduced brain water content and astrocytic swelling, and improved neurological outcomes and survivala fter ischemic stroke, as compared with wild-type mice. 53 
Injection of
Streptococcus pneumoniae causes meningitis-induced brain oedema; AQP4 null mice had significantly lower intracranial pressure and brain water accumulation, and a higher survival( 80% compared to 0% at 60h) as compared with wild type mice. 54 The reduced brain oedema seen in the AQP4-deficient mice highlights this channel as a potential target for drug therapy.
AQP1 is also an important therapeutic target in the brain. Imbalances between cerebral spinal fluid production and absorption can result in hydrocephalus, increased intracranial pressure, and mental retardation. Potential AQP1 blockers could have a protective effect in related disorders. In ar odent model of focal brain injury, AQP1-deficient mice demonstrated a five-fold reduction in osmotically drivenwater flux across the choroid epithelium, ar eduction in intracranial pressure and better survivalr ates than in the wild-type mice. 58 
Cancers
The upregulation of the water channel Aquaporin-1 (AQP1) is a unique feature of glioblastoma and certain other cancer types (breast and colon cancers), but the role of AQP1 in cancer has been difficult to evaluate, givent he relative lack of available pharmacological agents. 59, 60 Glioblastomas are invasive brain tumours that result from transformation of glial cells. In these rapidly lethal tumours the levelo fA quaporin-1 expression has been found to correlate with the aggressiveness of the disease, although the role of Aquaporin-1 in the disease process is not known. The age distribution in the world population of humans with brain tumours is bimodal, with peak incidences in children and adults between ages 45 to 70, and the highest rates seen in descendants of white European ethnic groups. Glioblastoma multiforme is the most common, malignant and aggressive form of brain tumour in adults, and accounts for 75-80% of primary brain gliomas as the 12 th leading cause of cancer-related death in men. With glioblastoma multiforme,most patients develop clinical symptoms overa short time span (three months) and die within 8-18 months of diagnosis. 61 Less than half of the patients diagnosed with glioblastoma live for 6 months, and only 3% survive for twoy ears. The incidence rate of glioblastoma per year is 3.32 in males and 2.24 in females per 100,000; of these cases, the majority are de novo glioblastomas, and rarely involveprogression from lowgrade gliomas (5%). 62 It is possible that block of AQP channels could slow the proliferation and migration of glioma cells. The upregulation of AQP1 expression in glioblastoma enables cancer cell volume regulation and promotes survival, proliferation, and migration. 63 The suggested role of AQP1 in the pathology of aggressive glioblastoma has been that the water channel provides for a regulated decrease in tumour cell volume which confers increased invasiveness of them through the restricted extracellular space of the central nervous system. However, ani nd epth consideration of the available data for AQPs in cancer (below) shows that more than just water channel function is involved; specific classes of AQPs are associated with the different classes of tumours, and the transformative effects of AQP overexpression on morphology,g rowth and proliferation cannot be mimicked by substitution of other classes of water channels.
In primary glioblastoma multiformae tumours, receptors and transporters that are involved in glutamate and GABAn eurotransmission are downregulated as compared with normal temporal lobe human brain tissue, buti nc ontrast, AQP1 expression is upregulated. 64 Glioma biopsies consistently showu pregulation of AQP1, though the expression is lost after the malignant cells are isolated and propagated in culture. In glioblastoma multiforme, upregulated AQP1 expression is proposed to contribute to oedema formation and cell motility.A QP1 expression was found to be strongly upregulated in human glial tumours available in the UCSF Neurosurgery Tissue Bank (36 samples), and might contribute to the formation of oedema associated with malignant glial tumours. 65, 66 In contrast, AQP4 does not have ano bvious link in glioblastoma. AQP4 is normally expressed in the perivascular endfeet of astrocytes; howeveri ng liomas, the normal localisation is lost and the channels are dispersed overt he cell surface. Levels of expression of AQP4 in Grade I to IV gliomas (World Health Organisation scale) were associated with the extent of oedema formation, but showed no correlation with patient survival. 67 While introduction of AQP4 did increase water permeability as expected, its additional effect was to enhance cell adhesion. The increase in AQP4 did not alter growth or migration. 63 In human lung cancers, AQP1 is overexpressed in adeno-and bronchoalveolar carcinomas, but not in squamous cell carcinoma or in normal lung tissue. 68 Overexpression of AQP1 in NIH-3T3 cells induces phenotypic changes characteristic of transformation, including cell proliferation and anchorage-independent growth in soft agar.U pregulation of AQP5 expression correlates with an increased rate of recurrence of non-small cell lung cancer, and a decreased chance of disease-free survival. Transfection of cell lines with wild type AQP5 altered the cell morphology to a fibroblastic phenotype, accompanied by the loss of cell-cell contacts, polarity,a nd epithelial markers, and the gain of mesenchymal cell markers; whereas mutant constructs lacking trafficking or phosphorylation signal sites did not cause these alterations. 69 Overexpression of human AQP5 induces phenotypic changes that are characteristic of transformation of cells in vitro and in vivo.A ni ncrease of proteinkinase−A mediated phosphorylation of AQP5 was observed in tumour cells and associated with increased proliferation. 70 In colorectal carcinomas, microarray profiling has shown that AQP1 can be considered to be a validated gene that discriminates colorectal cancer cells from adenomas and normal tissue. 71, 72 Overexpression of human AQP5 activates phosphorylation signaling cascades and induces proliferation in a colon cancer cell line. The effect is not replicated by the overexpression of other aquaporins AQP1 and AQP3, 73 indicating that the class of AQP linked to the pathogenic state depends on the type of tissue involved. AQP1 and AQP5 are expressed in colorectal cancer,f rom the early-stage of dysplasia through the late stages of colon cancer development, and in the metastatic lesions found in liver. 74 The implied role for AQP expression in tumorigenesis at early stages makes AQP an attractive target for potential therapeutic strategies.
In primary renal carcinomas, expression of AQP1 wass ignificantly higher in clear-cell and papillary forms, ev ena te arly stages before symptomatic presentation, as compared with the normal levels of expression of this protein in kidneyt issue samples. It is interesting to note that the addition of the AQP1 parameter to the University of California Los Angeles Integrated Staging System (UISS) prognostic score improvedt he accuracyo fp redictions of both cancer death and recurrence for all patient cohorts for clear-cell renal carcinoma. 75 In mammary carcinomas, tumour cell membranes shows ignificant expression of AQP1 that is not seen in the normal epithelial cells. 76 Together these results suggest that the cancerenhancing activity of AQPs is more than simply creating pathways for water flow, but that additional distinguishing features (such as capacity for linkages of AQPs into protein-protein signaling complexes, or regulation by intracellular signaling pathways) are also important. The role of AQPs in human cancer is emerging as an area of intense research interest. Analyses of AQP knockout mice have confirmed the expected functions of AQPs in epithelial fluid transport. However, some surprising roles for AQPs have emerged, in that AQPs have been found to promote cell migration, tumour angiogenesis, tumour extravasation and metastasis, to alter fat metabolism and more, by mechanisms that remain unknown. 60 Recognizing that AQP1 is a water channel and, under permissive conditions, also a cGMP-gated cation channel, 43, 45, 47 evidence in various tissues for a coupling of the cGMP signaling cascade to a physiological outcome that might involve AQP1 dual ion-and-water channel functions is of interest.
3,14
Summary
It appears that the call for development of pharmacological agents for aquaporins is being answered, and the field is poised for exciting progress in basic science and medicine. With the newc ompounds being identified, it is possible to finally begin testing for a role of AQP blockers in mitigating pathologies such as brain oedema, glioblastoma, breast and colon cancers, and manyo ther clinically important disorders.
